VCEL Vericel Corporation

18.63
+0.28  (+2%)
Previous Close 18.35
Open 18.44
Price To Book 8.59
Market Cap 832,658,759
Shares 44,694,512
Volume 349,009
Short Ratio
Av. Daily Volume 485,767
Stock charts supplied by TradingView

NewsSee all news

  1. Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C.

  2. Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow

    Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018Full Year 2019 Revenue Guidance Raised to $116 to $118 MillionConference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE

  3. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  4. Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,

  5. Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

    CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO &

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

BLA filing due 2Q 2020.
NexoBrid
Severe burns
Phase 2b topline data released March 2016. Full data released April 2016
ixmyelocel-T
Stem cells - Dilated Cardiomyopathy
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
MACI
Focal chondral cartilage defects in the knee.

Latest News

  1. Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C.

  2. Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow

    Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018Full Year 2019 Revenue Guidance Raised to $116 to $118 MillionConference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE

  3. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  4. Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,

  5. Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

    CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO &